GPC chronicles

GPC chronicles

GPC (FSE:GPC; GPCB), which was founded in 1997, originally was a genomics- and proteomics-based drug discovery company focused on oncology, infectious diseases and immunology. Since it in-licensed Orplatna satraplatin in 2002, its focus has turned to oncology drug discovery and development. At March 31, GPC had E111.3 million ($148.8 million) in cash. The weekly stock price for GPC is tracked below against selected events since the company's IPO on the Neuer Markt of the Frankfurt Stock Exchange in

Read the full 792 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE